Drug intelligence / Profile preview

diclofenac potassium + acetaminophen

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

A combination of diclofenac potassium, a nonsteroidal anti-inflammatory drug (NSAID), and acetaminophen (paracetamol), a non-NSAID pain reliever. This combination leverages two different mechanisms of action for pain relief. Diclofenac potassium works by inhibiting cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis which leads to decreased pain and inflammation. Acetaminophen's exact mechanism is not fully understood but is thought to work centrally on pain pathways. This combination may provide enhanced pain relief for various conditions including musculoskeletal pain, arthritis, menstrual cramps, and migraines.

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on diclofenac potassium + acetaminophen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on diclofenac potassium + acetaminophen.

Explore the full profile